Clinical trials landscape of conjunctivitis

GlobalData Healthcare 18th February 2020 (Last Updated February 18th, 2020 16:30)

GlobalData analysed the number of clinical trials examining conjunctivitis with start dates between January 1, 2009 and February 13, 2020.

Clinical trials landscape of conjunctivitis

GlobalData analysed the number of clinical trials examining conjunctivitis with start dates between January 1, 2009 and February 13, 2020.

The most common eye disease, conjunctivitis is an optic condition where the outermost layer of the white part of the eye becomes inflamed and irritated, resulting in the eye appearing pink and sore. Symptoms include pain, burning, and itchiness. Easily prevented by handwashing, conjunctivitis is initially caused by a virus that then leads to a bacterial infection. In adults the majority of cases seem to be viral, whereas in children most cases seem to be bacterial. Both viral and bacterial conjunctivitis are resolved without any treatment, but in bacterial cases topical antibiotics may be prescribed if symptoms are severe. Antihistamines may be used to help with symptom relief.

GlobalData analysed trials that focused on conjunctivitis. Figure 1 shows that the majority of trials were in Phase II (35.7%), followed by Phase III (29.3%) and Phase I (18.1%). The least amount of trials were conducted in Phase IV at 16.7%. Seventy-seven percent of these trials had industry-led sponsors whereas non-industry sponsors accounted for 22% of trials. The US conducted the highest amount of trials at 51.7%, followed by Spain (15.3%), Germany (14.0%), India (11.8%), and Poland (7.2%) (Figure 2).